HTA59 Budget Impact Analysis Of Migalastat Incorporation vs. Enzyme Replacement Therapies For Fabry Disease: Validation of a Cost-Assessment Tool In Brazilian Private Healthcare System
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.1844
https://www.valueinhealthjournal.com/article/S1098-3015(25)04401-8/fulltext
Title :
HTA59 Budget Impact Analysis Of Migalastat Incorporation vs. Enzyme Replacement Therapies For Fabry Disease: Validation of a Cost-Assessment Tool In Brazilian Private Healthcare System
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)04401-8&doi=10.1016/j.jval.2025.09.1844
First page :
Section Title :
Open access? :
No
Section Order :
11385